74 related articles for article (PubMed ID: 30484821)
1. Association of Transient Palmoplantar Keratoderma With Clinical and Immunologic Characteristics of Bullous Pemphigoid.
Duretz C; Antonicelli F; Muller C; Antonicelli N; Plee J; Viguier M; Bernard P
JAMA Dermatol; 2019 Feb; 155(2):216-220. PubMed ID: 30484821
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Dupilumab in Patients With Bullous Pemphigoid.
Zhao L; Wang Q; Liang G; Zhou Y; Yiu N; Yang B; Zhang G; Li W; Feng S; Shang P; Chen X; Zhu X; Zheng J; Pan M; Wang M
JAMA Dermatol; 2023 Sep; 159(9):953-960. PubMed ID: 37531116
[TBL] [Abstract][Full Text] [Related]
3. Pilot study investigating BP-180 in extracellular vesicles derived from blister fluid of bullous pemphigoid patients.
Gasparini G; Tasso R; Palamà MEF; Ciferri MC; Gentili C; Di Zenzo G; Provini A; Salemme A; Quarto R; Parodi A; Cozzani E
Arch Dermatol Res; 2023 Aug; 315(6):1837-1841. PubMed ID: 36763158
[TBL] [Abstract][Full Text] [Related]
4. Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients.
Chebani R; Lombart F; Chaby G; Dadban A; Debarbieux S; Viguier MA; Ingen-Housz-Oro S; Pham-Ledard A; Bedane CR; Picard-Dahan C; Berthin C; Dereure O; Konstantinou MP; Castel M; Jouen F; Joly P; Seta V; Duvert-Lehembre S; Le Roux C; Quereux G; Sassolas B; Brenaut E; Sin C; Richard MA; Bérard F; Giusti D; Belmondo T; Gille T; Caux F; Prost-Squarcioni C; Grootenboer-Mignot S; Alexandre M;
Br J Dermatol; 2024 Jan; 190(2):258-265. PubMed ID: 37792727
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of ELISA BP180 and BP230 Autoantibodies in Blister Fluid and Serum in the Diagnosis of Bullous Pemphigoid.
Nagarajan H; Mahadevan K; Rai R; Boppe A
Indian J Dermatol; 2023; 68(1):122. PubMed ID: 37151247
[TBL] [Abstract][Full Text] [Related]
6. Elevated levels of interleukin-9 in the serum of bullous pemphigoid: possible association with the pathogenicity of bullous pemphigoid.
Koga H; Teye K; Sugawara A; Tsutsumi M; Ishii N; Nakama T
Front Immunol; 2023; 14():1135002. PubMed ID: 37398641
[TBL] [Abstract][Full Text] [Related]
7. Dietary habits in Japanese patients with bullous pemphigoid: low intake of retinol.
Uozumi T; Serizawa N; Hagino T; Morita T; Mizuno M; Ichiyama S; Hoashi T; Saeki H; Matsuda H; Nakagawa K; Mitsui H; Kanda N
Eur J Dermatol; 2023 Aug; 33(4):394-403. PubMed ID: 37823490
[TBL] [Abstract][Full Text] [Related]
8. Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update.
Karakioulaki M; Eyerich K; Patsatsi A
Am J Clin Dermatol; 2024 Mar; 25(2):195-212. PubMed ID: 38157140
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and clinical markers of herpes simplex virus infection in oral lesions of bullous pemphigoid.
Zhang H; Yu M; Liang G; Li S; Zhao C; Jing K; Feng S
Front Immunol; 2024; 15():1387503. PubMed ID: 38698862
[TBL] [Abstract][Full Text] [Related]
10. A case of bullous pemphigoid following administration of anti-IL-31 receptor A antibody.
Masuyuki R; Sato E; Imafuku S
J Dermatol; 2024 Mar; ():. PubMed ID: 38507442
[TBL] [Abstract][Full Text] [Related]
11. Study of cytokine-induced immunity in bullous pemphigoid: recent developments.
Huang R; Hu L; Jiang F
Ann Med; 2023; 55(2):2280991. PubMed ID: 38109924
[TBL] [Abstract][Full Text] [Related]
12. Anti-interleukin 4 receptor α antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1-year follow-up: a monocentric real-world study.
Wang SH; Shan Y; Li SZ; Zuo YG
Front Immunol; 2023; 14():1165106. PubMed ID: 37545503
[TBL] [Abstract][Full Text] [Related]
13. The relationship between bullous pemphigoid and renal disease and related treatments: a review of the current literature.
Cui S; Zhang B; Li L
Expert Rev Clin Immunol; 2023; 19(11):1407-1417. PubMed ID: 37707350
[TBL] [Abstract][Full Text] [Related]
14. Spesolimab in the Management of Generalized Pustular Psoriasis With Concurrent Bullous Pemphigoid and Psoriasis.
Teshima R; Saito-Sasaki N; Hitaka T; Sawada Y
Cureus; 2024 May; 16(5):e60331. PubMed ID: 38883056
[TBL] [Abstract][Full Text] [Related]
15. Defective cathepsin Z affects EGFR expression and causes autosomal dominant palmoplantar keratoderma.
Malovitski K; Sarig O; Feller Y; Bergson S; Assaf S; Mohamad J; Pavlovsky M; Giladi M; Sprecher E
Br J Dermatol; 2023 Aug; 189(3):302-311. PubMed ID: 37210216
[TBL] [Abstract][Full Text] [Related]
16. Refractory Bullous Pemphigoid Successfully Treated with Reslizumab: A Possible Novel Therapeutic Modality.
Kwon HJ; Kim KH; Yoon JH
Ann Dermatol; 2023 May; 35(Suppl 1):S103-S106. PubMed ID: 37853878
[TBL] [Abstract][Full Text] [Related]
17. Successful Treatment of Psoriasis Combined with Bullous Pemphigoid with Dupilumab: A Case Report.
Liu JH; Gao Q; Ma WY; Cheng ZL; Luo NN; Hao PS
Clin Cosmet Investig Dermatol; 2023; 16():1583-1587. PubMed ID: 37359718
[TBL] [Abstract][Full Text] [Related]
18. The impact of human herpesvirus detection in pemphigus vulgaris.
Yang GQQ; Yap T; Martyres R; Varigos GA; Scardamaglia L
Australas J Dermatol; 2019 Aug; 60(3):e259-e261. PubMed ID: 30537024
[No Abstract] [Full Text] [Related]
19. Sex- and age-adjusted prevalence estimates of skin types and unpleasant skin sensations and their consequences on quality of life: results of a study of a large representative sample of the French population.
Misery L; Ezzedine K; Corgibet F; Dupin N; Sei JF; Philippe C; Joly P; Taieb C; Richard MA
Br J Dermatol; 2019 Jun; 180(6):1549-1550. PubMed ID: 30500070
[No Abstract] [Full Text] [Related]
20. Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.
Metyas S; Tomassian C; Messiah R; Gettas T; Chen C; Quismorio A
Curr Rheumatol Rev; 2019; 15(3):234-237. PubMed ID: 30499418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
